Dr Kieran O’Donovan

Dr Kieran O’Donovan has more than 25 years’ experience in the Biotech/Biopharma industry, starting his career heading up Research and Development in the then nascent probiotic industry before moving into the CMC arena at Protherics.

At Protherics, he led process development working on Fab fragments and recombinant proteins. In 2007, he moved to Ipsen as Head of Industrialisation, becoming Vice President of Toxins and Biologics in 2011 developing natural and recombinant toxins as well as recombinant proteins for the treatment of Hemophilia. 

Dr O’Donovan later took up the role of Head of CMC at ReNeuron in 2015 and was promoted to Director of CMC in 2017 leading the development, manufacture and clinical supply of their allogenic stem cell therapies. He holds a PhD in computer modelling of a bioreactor process from the University of Surrey and is a microbiologist by training.